Developmental programming in disease

Led by Karen Moritz, Director of the Child Health Research Centre, the flourishing Developmental Programming in Disease research group spans UQ’s Child Health Research Centre and School of Biomedical Sciences. Our group seeks to understand how disturbances during gestation contribute to a fetus’ increased risk of developing disease in adulthood. This research area seeks to identify organs and systems that are affected by prenatal insults and improve understanding of how to prevent or mitigate damage from occurring.

We work in the laboratory to develop preclinical models that mimic common prenatal insults, such as stress and alcohol exposure. The offspring’s development is then carefully analysed - alongside the metabolic, cardiovascular, renal, reproductive, neurological and behavioural functions of the adult and offspring - to understand the effects of these insults. We are particularly interested in how the kidney, placenta, heart, brain and ovaries of the developing fetus are impacted.

Our work also goes beyond the laboratory, and we collaborate on clinical projects with researchers and clinicians at the Lady Cilento Children’s Hospital and other hospitals and universities around Queensland and Australia. This collaborative work looks specifically at how the kidneys of babies and placentas of mothers are impacted by insults such as stress and alcohol.

Ultimately, our work aims to inform clinicians so they can help parents have healthier babies less likely to develop disease in later life. This can be achieved by making prospective parents aware of their behaviour and lifestyle choices, and how such choices may impact on a developing baby and their risk of disease in later life.

This kind of information will empower parents to prevent damage from occurring in the first place, and inform the development of interventions that can mitigate damage when an insult does occur.

Current Projects

Periconceptional alcohol exposure: Programming long-term health in offspring

Approximately 80% of Australian women drink alcohol around the time of conception. Whilst many cease or reduce alcohol consumption once pregnancy is confirmed, the long term consequences of exposure around conception are largely unknown. We have developed a pre-clinical rat model of periconceptional alcohol exposure (PCE) and demonstrated that exposure results in fetal growth restriction, impairments in placental development and metabolic, renal and cardiac dysfunction in offspring in adult life. Given that many women drink prior to recognition of pregnancy, the urgent challenge is to understand the mechanisms contributing to disease and design effective intervention strategies.

We currently have projects involving our rat model that are further characterising the impact of PCE on neonatal and long-term offspring health. These include projects involving the development and function of the kidneys (nephron/tubule number and structure; measures of renal function), the heart (vessel morphology/structure; measures of cardiovascular function), the brain and circadian systems (behaviour and circadian rhythms) and the ovary (ovarian reserve, follicle development and fertility).

In addition to describing the offspring phenotypes produced from this periconceptional insult, our lab is currently focused on determining molecular mechanisms underlying the programming of disease outcomes in offspring. We are examining impacts on uterine-embryo interactions at the time of implantation which impact on trophoblast cell invasion and subsequent placental structure. We are also testing the hypothesis that there is altered activity and methylation of the glucocorticoid receptor (GR), which is central to the activity of the hypothalamic-pituitary-adrenal (HPA) axis in both the mother and offspring in response to a stressor. Given that our perturbation is occurring during pregnancy prior to fetal organ and placental formation, epigenetic changes or alterations to maternal physiology are likely mechanisms driving the observed offspring phenotypes.

We are also focusing on testing a safe and feasible intervention during pregnancy. Choline is an essential nutrient and methyl donor and thus can influence DNA methylation. Supplementation with choline has been shown to be safe in human pregnancies. We are currently testing the potential for choline to ameliorate the impacts of PCE placental development and offspring organ function. In our preclinical rodent model of periconceptional alcohol exposure.

Co-supervision: Dr David Simmons, Dr Lisa Akison, Prof Vicki Clifton, Dr Oliver Rawashdeh

Prenatal hypoxia and the risk for adult onset renal and cardiovascular disease

Adequate oxygen tension in the developing fetus is vital for optimal organ development. Episodes of hypoxia during gestation are common, but may have profound implications for fetal growth and adult health outcomes. We combine physiological measurements with histological and molecular analyses to examine cardiovascular and renal health of offspring born from pregnancies complicated by reduced oxygenation.

We have demonstrated that fetal hypoxia increases vulnerability of offspring, particularly males, to cardiovascular and renal disease in adulthood. Furthermore, the symptoms of cardiovascular and kidney disease worsen significantly following additional stressors, such as ageing and a high salt diet. Our current focus is the impact of fetal environmental stressors on the developing kidney, particularly the structure and function of the renal tubules and collecting duct system.

Co-supervision: Sarah Walton

Emerging therapies for diabetes and complications: Effects on metabolic, cardiovascular and renal function

Diabetes mellitus affects more than 415 million people worldwide and many will experience premature mortality due to cardiovascular and/or kidney disease. Blood glucose control is the primary strategy to prevent vascular complications in diabetes. However, there is no guarantee that achieving near-normal blood glucose levels, particularly in patients with long-standing type 2 diabetes, will prevent the onset and progression of micro- and/or macrovascular diseases. This research program aims to refine preventative and interventional treatments for cardiovascular and kidney diseases in diabetes.

At present, we are studying the therapeutic potential of a new anti-diabetic agent, SGLT2 inhibitor, for the treatment of cardiovascular and kidney disease in diabetes. This agent targets the kidney to prevent glucose reabsorption, thereby promoting urinary glucose excretion and lowering blood glucose levels. In a recent clinical trial, this agent reduced cardiovascular mortality and the progression of kidney disease in patients with type 2 diabetes. However, the mechanisms underlying these benefits are unknown and we aim to identify what they are to design more specific treatments. We use whole-animal physiological techniques to study metabolic, cardiovascular, and kidney disease. Molecular approaches are utilised to gain a better understanding of the mechanisms involved.

Co-supervision: Dr Linda Gallo

Effect of prenatal insults on the developing placenta

Normal placental function is essential for optimal fetal growth. Thus, many adverse perinatal outcomes including miscarriage, intra-uterine growth restriction (IUGR) and even some fetal defects can be attributed to poor placental function. These can often occur in pregnancies complicated by conditions such as gestational diabetes, asthma/hypoxia, stress or preeclampsia. Our lab, in conjunction with clinical collaborators, is interested in examining placental development, morphology and function in compromised pregnancies.

Transport of glucose from mother to fetus is particularly critical to meet fetal nutrient demands and is controlled by a number of specific placental glucose transporters. In both humans and rodents, glucose can also be stored in the placenta in the form of glycogen, however the function of this glycogen deposition remains a matter of debate. Some evidence suggests placental glycogen provides a source of fuel for the placenta itself, while other studies suggest placental glycogen is stored for later use by the fetus in times of need. While the significance of placental glycogen deposition remains elusive, mounting evidence from both human and animal studies indicates that altered glycogen deposition accompanies many pregnancy complications that adversely affect fetal development. Our lab is interested in determining the circumstances under which glycogen is stored and/or released in the placenta and what role altered placental glycogen deposition may play in inappropriate fetal growth.

Maternal insults during pregnancy also typically result in activation of the hypothalamus-pituitary-adrenal (HPA) axis in both the mother and offspring resulting in elevated glucocorticoids (GC) (cortisol in humans and corticosterone in rodents). GCs exert their action predominantly through binding to the glucocorticoid receptor (GR) which is expressed in many tissues including the placenta. However, activity of the GR is dependent upon the specific isoforms present which in turn is dependent upon DNA methylation of GR tissue-specific promoters. We hypothesise that changes in specific GR isoforms may contribute to altered GR signaling pathways involved in metabolism, growth and inflammation in the placenta.

Co-supervision: Prof Vicki Clifton, Dr Marloes Nitert Dekker

Effect of prenatal insults on the developing kidney and implications for adult disease

In Australia, around 1.7 million people have clinical evidence of chronic kidney disease (CKD) and 3.7 million people are affected by cardiovascular disease. Abnormal kidney development, in particular, a low nephron endowment, directly correlates with an increased risk of these diseases in adulthood. A reduced nephron number, resulting in impaired glomerular filtration rate (GFR) can occur as a result of low birth weight or premature delivery. However, reduced nephron number alone cannot fully explain the increased prevalence of CKD and hypertension. Unlike nephrogenesis, which ceases around 36 weeks of gestation in humans, the development of the renal tubular system, particularly within the papilla, starts during embryogenesis and continues after birth, not reaching functional maturation until 12-18 months of age. Impairments in papillary tubule development are associated with reduced renal function in children. However, the association between abnormal development of the renal papilla and increased risk of kidney disease in the adult has never been studied. This project will use both clinical and preclinical studies to determine if impaired development of the renal papilla contributes to CKD in adults. Papilla development in normal and premature babies will be examined by ultrasound images and adult kidneys examined using archival kidney samples. Preclinical animal models will evaluate how papilla development and functional maturation is affected by common perturbations including prenatal hypoxia, birth asphyxia and preterm birth. Our ultimate goal is to develop a clinically relevant postnatal intervention that can improve kidney outcomes following an early life perturbation. This project involves clinical collaborators from the Lady Cilento Children’s Hospital in Brisbane and Townsville Hospital. Co-supervision: Dr Joan Li


Our lab utilises a variety of whole animal/in vivo physiology, in vitro cell culture, molecular biology (protein and mRNA), histology/stereology and behavioural assays. This includes:

  • Quantitative real-time PCR for gene expression analysis
  • Western blot for protein quantification
  • Immunohistochemistry and immunofluorescence for protein localisation in tissues
  • Immunofluorescence of cell types within the pre-implantation blastocyst
  • In situ hybridisation of trophoblast cell types within the immature and definitive placenta
  • Pre-clinical animal models
  • Langendorff heart perfusion assays to measure cardiac function in vitro or isolated perfused heart assay to examine cardiac contractile strength and heart rate in vitro.
  • Pressurised myography to measure physiological function and properties of isolated vessels
  • Radiotelemetry measurement of blood pressure, heart rate and activity in freely moving animals
  • In vitro culture to measure trophoblast outgrowth of pre-implantation blastocysts and their differentiation into invasive giant cells
  • Cell culture of trophoblast stem cells to examine differentiation into downstream lineage restricted subtypes
  • Histology and histopathology
  • Microscopy (including confocal)
  • Stereology for assessment of nephron endowment in the kidney, renal tubule length in the kidney, follicle numbers in the ovary and volume measurements for specific cell compartments in the placenta
  • Non-invasive behavioural testing to assess neurological function in rodents, including measures of anxiety, exploratory behaviour and spatial learning/memory
  • Measurement of hormones in plasma by RIA and ELISA
  • Metabolic assessments such as insulin tolerance test (ITT) and glucose tolerance test (GTT) in rodents
  • DEXA for body composition measurement in rodents

NB: All animal experimentation is subject to approval by the University of Queensland Animal Ethics Committee and adheres to the Australian code for the care and use of animals for scientific purposes (National Health and Medical Research Council, 8th Edition, 2013).


Dr David Simmons
School of Biomedical Sciences
Mater Medical Research Institute
Translational Research Institute
The University of Queensland

Dr Marloes Nitert Dekker
School of Chemistry and Molecular Biosciences
Centre for Clinical Research
The University of Queensland

Dr Oliver Raweshdeh
School of Biomedical Sciences
The University of Queensland

Prof Mary Wlodek
Department of Physiology
The University of Melbourne

Prof Vicki Clifton
Mater Medical Research Institute
Translational Research Institute
The University of Queensland

Meet our team

Professor Karen Moritz is the Director of the Child Health Research Centre and leads the Developmental Programming in Disease group. The group is split between the Child Health Research Centre and UQ School of Biomedical Sciences.

Meet our research team